醋硝香豆素(Acenocoumarol) - 药物靶点：NQO1 x VKOR_在研适应症：血栓栓塞_专利_临床

概要

基本信息

药物类型

小分子化药

别名

3-(alpha-(4'-Nitrophenyl)-beta-acetylethyl)-4-hydroxycoumarin、3-(alpha-(p-Nitrophenol)-beta-acetylethyl)-4-hydroxycoumarin、3-(alpha-Acetonyl-4-nitrobenzyl)-4-hydroxycoumarin

+ [21]

靶点

NQO1 x VKOR

作用机制

NQO1抑制剂(苯醌还原酶-1抑制剂)、VKOR抑制剂(维生素K环氧化物还原酶复合体1抑制剂)、维生素K拮抗剂

治疗领域

心血管疾病

在研适应症

血栓栓塞

非在研适应症-

原研机构-

在研机构-

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构

分子式C19H15NO6

InChIKeyVABCILAOYCMVPS-UHFFFAOYSA-N

CAS号152-72-7

关联

14

项与醋硝香豆素相关的临床试验

NCT03153150 / Completed临床3期IIT

Start or STop Anticoagulants Randomised Trial (SoSTART) After Spontaneous Intracranial Haemorrhage

Primary research question: For adults surviving spontaneous (non-traumatic) symptomatic intracranial haemorrhage with persistent/paroxysmal atrial fibrillation/flutter (AF), does starting full treatment dose oral anticoagulation (OAC) result in a beneficial net reduction of all serious vascular events compared with not starting OAC?
Trial design: Investigator-led, multicentre, randomised, open, assessor-masked, parallel group, clinical trial of investigational medicinal product (CTIMP) prescribing strategies. Investigators plan for a pilot phase, followed by a safety phase.

开始日期2018-03-28

申办/合作机构

The University of Edinburgh

[+1]

EUCTR2016-003086-25-NL / Unknown status临床3期IIT

More precise dosing of acenocoumarol in patients aged 80 and above, a pilot study - Eighty and a half

开始日期2017-04-19

申办/合作机构

University Medical Center Groningen

NCT02826200 / Unknown status临床4期IIT

Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography

The RETORIC study is a prospective cohort study with a primary aim to assess the incidence and independent predictors of reduced leaflet motion and valve thrombosis after TAVI procedure using multimodality imaging strategy comprising cardiac CT, transesophageal echocardiography (TEE) and transthoracic echocardiography (TTE). As a secondary aim we will assess the incidence of stroke and transient ischemic attack (TIA) in patients with reduced leaflet motion and/or thrombosis when compared with those with normal leaflet function. In addition we will randomize patients with reduced leaflet motion and/or valve thrombosis to single antiplatelet therapy plus oral anticoagulation therapy versus standard therapy.
The primary outcome of the nested randomized trial will be the presence of reduced leaflet motion and/or valve thrombosis after 4 months, the secondary outcome is the presence of ischemic changes in brain demonstrated by MRI.

开始日期2016-07-01

申办/合作机构-

100 项与醋硝香豆素相关的临床结果

登录后查看更多信息

100 项与醋硝香豆素相关的转化医学

登录后查看更多信息

100 项与醋硝香豆素相关的专利（医药）

登录后查看更多信息

1,414

项与醋硝香豆素相关的文献（医药）

2024-12-01·Annales de Cardiologie et d'Angéiologie

La fibrillation atriale à l'Hôpital Principal de Dakar au Sénégal : résultats et limites de la prise en charge

Article

作者: Khadidiatou, Dia ; Cherif, Mboup Mouhamed ; Madjiguène, Ka Mame ; Niang, Mboup Waly ; Rabab, Yassine ; Marième, Diop ; Tidiane, Ndao Serigne Cheikh

OBJECTIVESThe aim of the study was to determine the prevalence of AF in the cardiology department of the Hospital Principal of Dakar, then to evaluate the clinical, paraclinical, etiological and evolutionary profiles of AF and finally to identify the limits of its management in our context.PATIENTS AND METHODSThis was a retrospective, descriptive, analytical, mono-centric study carried out at Hospital Principal of Dakar from January 2019 to August 2021. Were included, all patients admitted for atrial fibrillation, or patients who presented an atrial fibrillation during hospitalization, confirmed by electrocardiogram or long-term electrocardiographic recording during the study period.RESULTSThe prevalence of atrial fibrillation during the period of our study compared to the hospital population was 7.71%, with a sex ratio of 1.03. The mean age was 67.88 ± 14.09 years. We noted that 83.64% of patients had at least one cardiovascular risk factor, with 56.36% suffering from hypertension, 50.91% of sedentary person and 23.64% of diabetics. Clinically, 92.72% of the patients were symptomatic, with dyspnea predominating (70.91%). Cardiac arrhythmia was present in 85.45% of patients, and congestive heart failure in 47.27%. Long-term electrocardiographic recording was performed in 10 patients, showing 50% of paroxysmal atrial fibrillation. Sixty-three patients (57.27%) had permanent AF, twenty-three patients (20.91%) had persistent AF, fourteen patients (12.73%) had long-term persistent AF and ten patients (9.09%) had paroxysmal AF. Transthoracic echocardiography showed 57.27% of left atrial dilatation and 72.3% of reduced left ventricular ejection fraction. Etiologies for cardiac causes were dominated by dilated cardiomyopathy (21.82%), followed by ischemic heart disease (17.27%). In terms of treatment, the most commonly used molecule was bisoprolol (38.18%), followed by digoxin (21.81%). Anticoagulants were used in 85.46% of cases. Acenocoumarol alone was used in 69.09% of patients. Drug-induced cardioversion was attempted in 2 patients without success, and 4 patients benefited from external electric shock with 3 successes. Most patients had a favorable outcome, but 34.54% suffered hemodynamic complications (18.18%) and thromboembolic ones as well (16.36%). In-hospital mortality in our series was 20%. It was significantly related to heart failure, with a left ventricular ejection fraction < 35% (p < 0.001).CONCLUSIONAtrial fibrillation is serious because of its hemodynamic, thromboembolic and rhythmic complications. The high mortality is explained by the underlying condition, but also by the delay in management with late diagnosis and, above all, the unavailability of ablation procedures in our context.

2024-09-01·Radiology Case Reports

Prenatal sonographic diagnosis and postnatal outcomes of fetal intracranial hemorrhage: Two case report

Article

作者: Yen, Vu T H

Intracranial hemorrhage (ICH) in pregnancy, estimated at 1 in 10,000 cases, presents significant diagnostic challenges prenatally despite advanced imaging techniques such as ultrasonography (US) and magnetic resonance imaging (MRI). Detecting ICH is crucial for pregnancy management and future treatment decisions aimed at improving fetal survival and reducing brain damage. This report presents the diagnosis and outcomes of 2 cases of prenatal ICH. The first case involves a 30-year-old pregnant woman with irregular prenatal care diagnosed with ICH at 32 weeks of gestation via US and MRI. She chose to continue the pregnancy, delivering a 3160 g male infant at 36 weeks via cesarean section. Following NICU care including resuscitation and ventriculoperitoneal shunt placement, the infant was discharged. Subsequent examinations showed a reduction in ventricle size. In the second case, a 27-year-old woman taking acenocoumarol for a mechanical heart valve developed fetal subdural hemorrhage detected by US and MRI. She opted to terminate the pregnancy, resulting in a stillborn male infant weighing 1530 g. Fetal ICH presents with varying severity and prognostic implications, diagnosed and graded using US. Fetal cranial MRI may help clarify the etiology. Management remains controversial, with termination of pregnancy potentially warranted in severe cases due to poor prognosis. Further research is needed to refine management and improve outcomes in fetal ICH.

2024-08-01·Revista Clínica Española (English Edition)

Oral anticoagulant treatment in atrial fibrillation: the AFIRMA real-world study using natural language processing and machine learning

Article

作者: group, S. R. ; Fernández de Cabo, S ; Fernandez de Cabo, S. ; Cosín-Sales, J ; Martínez-Sanchez, L ; Anguita, M ; Anguita, M. ; Arias-Cabrales, C. ; Suárez, C ; Arumi, D ; Arumi, D. ; Martinez-Sanchez, L. ; Arias-Cabrales, C ; Suarez, C. ; Cosin-Sales, J.

INTRODUCTIONOral anticoagulation (OAC) is key in atrial fibrillation (AF) thromboprophylaxis, but Spain lacks substantial real-world evidence. We aimed to analyze the prevalence, clinical characteristics, and treatment patterns among patients with AF undertaking OAC, using natural language processing (NLP) and machine learning (ML).MATERIALS AND METHODSThis retrospective study included AF patients on OAC from 15 Spanish hospitals (2014-2020). Using EHRead® (including NLP and ML), and SNOMED_CT, we extracted and analyzed patient demographics, comorbidities, and OAC treatment from electronic health records. AF prevalence was estimated, and a descriptive analysis was conducted.RESULTSAmong 4,664,224 patients in our cohort, AF prevalence ranged from 1.9% to 2.9%. A total of 57,190 patients on OAC therapy were included, 80.7% receiving Vitamin K antagonists (VKA) and 19.3% Direct-acting OAC (DOAC). The median age was 78 and 76 years respectively, with males constituting 53% of the cohort. Comorbidities like hypertension (76.3%), diabetes (48.0%), heart failure (42.2%), and renal disease (18.7%) were common, and more frequent in VKA users. Over 50% had a high CHA2DS2-VASc score. The most frequent treatment switch was from DOAC to acenocoumarol (58.6% to 70.2%). In switches from VKA to DOAC, apixaban was the most chosen (35.2%).CONCLUSIONSUtilizing NLP and ML to extract RWD, we established the most comprehensive Spanish cohort of AF patients with OAC to date. Analysis revealed a high AF prevalence, patient complexity, and a marked VKA preference over DOAC. Importantly, in VKA to DOAC transitions, apixaban was the favored option.

100 项与醋硝香豆素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D07064	醋硝香豆素	B01AA07	DB01418

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
血栓栓塞	-	-	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02696226 (CTgov)	N/A	血栓形成 \| 主动脉瓣疾病	3	SAVR Warfarin (SAVR Warfarin Arm)	構襯網膚膚衊壓壓衊鬱(夢壓齋繭築鹹襯窪廠鏇) = 鬱觸選齋夢鬱鹹淵顧觸齋餘製構齋鏇夢壓鹹構 (廠簾築淵鑰鑰膚網艱繭, 憲鑰鏇積製願餘鑰蓋築 ~ 範齋選鹹夢獵艱襯鬱壓) 更多	-	2017-11-08
				Warfarin+clopidogrel (TAVR Warfarin and Clopidogrel Arm)	構襯網膚膚衊壓壓衊鬱(夢壓齋繭築鹹襯窪廠鏇) = 範網選鹽構壓醖壓壓顧齋餘製構齋鏇夢壓鹹構 (廠簾築淵鑰鑰膚網艱繭, 築壓觸壓積夢顧壓鹹蓋 ~ 齋選簾顧淵襯築製憲願) 更多